TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25825944
Drug: Continual uFSH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continual uFSH (75 U, 3 times a week) and hCG (2000 U, twice a week)
Study: 25825944
Drug: Sequential uFSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential uFSH (75 U, 3 times a week every other 3 months) and hCG (2000 U, twice a week)
Study: 24393576
Drug: Catheter ablation
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter ablation without antiarrhythmic drug therapy
Study: 19265599
Drug: Recommended drugs
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended drugs
Study: 19265599
Drug: Drugs only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs only to be used in special circumstances
Study: 19265599
Drug: Drugs which
Normalized name: Autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence
DrugBank: Atidarsagene autotemcel (DB17538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs which should not be used in normal circumstances
Study: 15185523
Drug: Urostim and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urostim and antibiotic
Study: 9563668
Drug: Beta-lactamase stable
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactamase stable antibiotic
Study: 8206773
Drug: Nurse-delivered smoking
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-delivered smoking cessation intervention (three structured sessions during hospitalization, followed by weekly phone calls for 5 weeks after discharge)
Study: 3207608
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) with or without radiotherapy (RT)
Study: 3207608
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (CT, RT, or both)
Study: 29459462
Drug: CABG+medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CABG+medical therapy (MED)
Study: 18463831
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) guided antibiotic therapy (duration: 5.9±1.7 days)
Study: 18463831
Drug: Standardized duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized duration of antibiotic therapy (control group, duration: 7.9±0.5 days)
Study: 7437277
Drug: Paracetamol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1.0 g
Study: 2060559
Drug: Paracetamol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1.0 g plus codeine 60 mg
Study: 4028621
Drug: Aqueous methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of 25 mg doxepin hydrochloride
Study: 4028621
Drug: Aqueous methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of 600 mg ibuprofen
Study: 4028621
Drug: Aqueous methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of 50 mg indomethacin
Study: 4028621
Drug: Aqueous methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of 975 mg aspirin
Study: 4028621
Drug: Aqueous methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of lactose placebo
Study: 29688502
Drug: Subcutaneous semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous semaglutide 0.5 mg once weekly
Study: 29688502
Drug: Subcutaneous semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous semaglutide 1.0 mg once weekly
Study: 20505674
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg once a day, titrated to 16 mg after 1 month
Study: 20505674
Drug: Olmesartan 10
Normalized name: amlodipine-olmesartan 10 mg-20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 10 mg once a day, titrated to 20 mg after 1 month
Study: 12627985
Drug: Lamotrigine 500
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine 500 mg/day
Study: 8739928
Drug: Dextran infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran infusion (7 ml/kg)
Study: 7952793
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 200 micrograms
Study: 6867983
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 400 micrograms
Study: 6867983
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 800 micrograms
Study: 6867983
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 1600 micrograms
Study: 18469572
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (all doses)
Study: 30653490
Drug: AmBisome monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome monotherapy (40 mg/kg)
Study: 30653490
Drug: AmBisome (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome (30 mg/kg) with miltefosine (100 mg/day for 28 days)
Study: 24694769
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (TAT; DAT with cilostazol)
Study: 29118299
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAT; aspirin and clopidogrel)
Study: 22480130
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) in doses proportional to daily opioid doses (group P)
Study: 22480130
Drug: Dose titration
Normalized name: Rebif Rebidose Titration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose titration of FBT starting with an initial dose of 100 µg (group T)
Study: 16195824
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg of GnRH agonist triptorelin acetate depot (Group I)
Study: 16195824
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg triptorelin acetate daily (Group II)
Study: 11788184
Drug: Continuous estrogen-progestin
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous estrogen-progestin therapy (Conjugated Equine Estrogens and Medroxyprogestin without interruption)
Study: 11788184
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen (Conjugated Equine Estrogens over 25 days with Medroxyprogestin beyond the 14th day)
Study: 8067712
Drug: Propionibacterium granulosum
Normalized name: Propionibacterium acnes
DrugBank: Propionibacterium acnes (DB19089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionibacterium granulosum KP-45, 10 mg administered intravenously between the seventh and third day prior to surgical treatment.
Study: 8067712
Drug: Propionibacterium granulosum
Normalized name: Propionibacterium acnes
DrugBank: Propionibacterium acnes (DB19089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionibacterium granulosum KP-45 (treatment group)
Study: 1092425
Drug: Nimorazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimorazole (1 g orally at 12-hourly intervals for three doses)
Study: 1092425
Drug: Metronidazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (200 mg three times daily for 7 days)
Study: 30375890
Drug: Flaxseed (15g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (15g daily for 7 weeks)
Study: 19650984
Drug: Clonidine transdermal
Normalized name: Clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine transdermal patch
Study: 28697832
Drug: Haloperidol tablets
Normalized name: Haloperidol Tablets
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol tablets
Study: 18692790
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone therapy (5 microg of ethinyl E(2) and 1 mg of norethindrone acetate)
Study: 9286859
Drug: Antenatal betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal betamethasone (12 mg at a 12-h interval)
Study: 12769404
Drug: Topical retinoids
Normalized name: tocopheryl retinoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoids
Study: 2959308
Drug: Betahistine (H1-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (H1-receptor agonist)
Study: 2958072
Drug: Histamine (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (combined H1- and H2-receptor agonist)
Study: 2959308
Drug: Impromidine (H2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impromidine (H2-receptor agonist)
Study: 30031389
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dosages of 800 IU vitamin D3
Study: 30031389
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 300,000 IU vitamin D3
Study: 25291578
Drug: 3.75 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 µg of avian influenza Anhui vaccine with MF59 adjuvant
Study: 25291578
Drug: 3.75 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 µg of avian influenza Anhui vaccine without MF59 adjuvant
Study: 25291578
Drug: 7.5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 µg of antigen with MF59 adjuvant
Study: 25291578
Drug: 90 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 µg of unadjuvanted vaccine
Study: 25291578
Drug: 7.5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 µg plus adjuvant
Study: 22893166
Drug: COPE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPE plus usual treatment (n = 55)
Study: 22893166
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment alone (control) (n = 48)
Study: 20832701
Drug: Acetazolamide 85
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide 85 mg
Study: 16650180
Drug: Levocetirizine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine, 5 mg once daily
Study: 12464713
Drug: Paroxetine up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine up to 20 mg/day
Study: 8859144
Drug: Breakfast at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast at school (200 ml of 3%-fat milk and 30 g of sugared cornflakes for 14 days)
Study: 8218759
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ranitidine (50 mg bolus + 0.125 mg.kg/h)
Study: 8218759
Drug: Repeated boluses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated boluses of ranitidine (50 mg every 6 h)
Study: 22210797
Drug: Baseline period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline period (no treatment)
Study: 3493738
Drug: cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporin A (CyA) 5 mg/kg body weight for six months
Study: 17125809
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) programme against filariasis
Study: 15235203
Drug: Conventional regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional regimen of intravenous fluid administration (Control)
Study: 7024866
Drug: Ibuprofen (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1600 mg/day)
Study: 3163538
Drug: Ibuprofen (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1600 mg/day) plus Meptazinol (400 mg/day)
Study: 30446471
Drug: Water vapor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water vapor thermal therapy (Rezūm procedure)
Study: 14688490
Drug: Combination drug
Normalized name: combination drugs used in erectile dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination drug therapy
Study: 20875125
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment group (lunchtime walking intervention)
Study: 18230943
Drug: Rogerian Supportive
Normalized name: geranium oil, Algerian type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rogerian Supportive Therapy (ST)
Study: 14639584
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with 0.2 mg/kg of alpha‐galactosidase A every 2 weeks
Study: 10952699
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid volumes (60 ml/kg on day 1 progressing to 150 ml/kg on day 7)
Study: 1298545
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg once a day (n=13)
Study: 1298545
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg once a day + Gemfibrozil 600 mg daily (n=11)
Study: 7582386
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg once a day
Study: 1298545
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg once a day + Gemfibrozil 600 mg daily
Study: 6209346
Drug: Presurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presurgical treatment with 3.5 X 10(4) units of leukocyte interferon/kg (3 injections)
Study: 6209346
Drug: Postsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postsurgical treatment with placebo (7 injections)
Study: 6209346
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 injections)
Study: 31257591
Drug: AMX +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMX + MET (500 mg three times a day and 400 mg three times a day for 7 days)
Study: 31257591
Drug: CLM (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLM (500 mg twice a day for 7 days)
Study: 12042231
Drug: Brief cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive-behavioural therapy (CBT), n=257
Study: 12042231
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control group), n=165
Study: 10192710
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine given simultaneously with DTaP vaccine
Study: 7762855
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg diltiazem
Study: 15502049
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg lidocaine
Study: 1702899
Drug: Isoprinosine 3
Normalized name: Isoprénaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprinosine 3 g/day for 28 days
Study: 6775742
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of papaveretum (1 mg/min loading dose, followed by 8 times the loading dose over 48 hours)
Study: 6775742
Drug: Intermittent intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intramuscular dose of papaveretum (0.25 mg/kg at four hourly intervals as necessary)
Study: 31886526
Drug: Pharmaceutical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical and other innovative therapeutic strategies
Study: 16961448
Drug: 3-S therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-S therapy (8 weeks)
Study: 10697060
Drug: Estrogen 1.25
Normalized name: Conjugated estrogen 1.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen 1.25 mg/d
Study: 3544189
Drug: Low-dose antacid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacid (400 mg of aluminum hydroxide plus 400 mg of magnesium hydroxide four times a day)
Study: 3544189
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (cimetidine and low-dose antacid)
Study: 30388194
Drug: Tafenoquine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine (n = 12), single 200-mg dose on days 1, 2, 3, and 10
Study: 22914392
Drug: Progesterone treatment
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone treatment (n=258)
Study: 22914392
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n=265)
Study: 19892086
Drug: Manualized and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualized and workbook-driven individual cognitive-behavioral treatment for social anxiety disorder
Study: 19892086
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment for 20 weeks
Study: 17684877
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hyperbaric bupivacaine 0.5% + 25 microg fentanyl
Study: 17684877
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg hyperbaric bupivacaine 0.5% + 25 microg fentanyl
Study: 17684877
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hyperbaric bupivacaine 0.5% + 25 microg fentanyl
Study: 9650877
Drug: Herbal extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal extract mouthwash (6.3 mg/ml)
Study: 8583518
Drug: Recovery Attitude
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery Attitude and Treatment Evaluator (RAATE) completed by patients
Study: 8583518
Drug: Recovery Attitude
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery Attitude and Treatment Evaluator (RAATE) completed by clinicians
Study: 8583518
Drug: Less than
Normalized name: IgA less than or equal to 50 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less than 1 month of treatment
Study: 2678688
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon (100 x 10(6) IU)
Study: 2678688
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon (10 x 10(6) IU)
Study: 10208143
Drug: Oxandrolone, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone, 20 mg/d
Study: 7885427
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patches (15 mg for 16 hours daily)
Study: 356980
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus DTIC and actinomycin D (starting at 650 mg/m2 and 1 mg/m2 respectively, courses repeated at 3-4 week intervals)
Study: 30538068
Drug: Systemic therapy-naive
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy-naive patients with BM
Study: 30538068
Drug: Patients developing
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients developing BM while on first-line systemic therapy
Study: 30538068
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without BM while on first-line systemic therapy
Study: 27756786
Drug: LHRH agonist/bicalutamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist/bicalutamide
Study: 24119182
Drug: Carvedilol 12.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5/25 mg daily
Study: 24119182
Drug: Metoprolol 50/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50/100 mg daily
Study: 24119182
Drug: Nebivolol 2.5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 2.5/5 mg daily
Study: 21428248
Drug: Metronidazole vaginal
Normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole vaginal suppository 1/night for 1 week
Study: 21428248
Drug: Econazole vaginal
Normalized name: econazole Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Econazole vaginal suppository 1/night for 3 days
Study: 19427775
Drug: Crocus sativus
Normalized name: CROCUS SATIVUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocus sativus (saffron) 200mg tablet taken daily for ten days
Study: 16997936
Drug: DHEA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA treatment (75 mg daily for an average of 17.6 weeks)
Study: 363252
Drug: Additional early
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional early therapy
Study: 19420003
Drug: Single intracoronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intracoronary infusion of bone marrow mononuclear cells (BMC) (1.9 +/- 1.2 x 10^8) at 3-7 days after AMI
Study: 19420003
Drug: BMC administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BMC administration both at 3-7 days (2.0 +/- 1.4 x 10^8) and at 3 months (2.1 +/- 1.7 x 10^8)
Study: 19420003
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection at 3-7 days